18 Nov 2014 CKD Pharmaceuticals achieves tolerated well, and showed a comparable PK, PD, and tolerability profile to that of NESP® (Darbepoetin alfa).
17 Nov 2014 DiaMedica Announces Top-line Results of Phase IIa Clinical Trial of DM199 for Type 2 Diabetes
17 Nov 2014 Allena Pharmaceuticals Presents Phase 1 Data on ALLN-177 at American Society of Nephrology Kidney Week 2014
17 Nov 2014 Portola, Bristol-Myers Squibb and Pfizer Announce Statistically Significant Results from the First Part of the Phase 3 ANNEXA™-A Studies of Investigational Andexanet Alfa with Eliquis (apixaban)
17 Nov 2014 Zealand advances its proprietary stable glucagon analogue for severe hypoglycemia in diabetes into clinical development
17 Nov 2014 The Medicines Company Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters and Was Well-Tolerated in Healthy and Coronary Artery Disease (CAD) Patients
12 Nov 2014 CSL Limited Launches AEGIS-I, a Phase 2b Clinical Study of CSL112, a Novel Apolipoprotein A-I Infusion Therapy Designed to Rapidly Remove Cholesterol from Arteries and Stabilize Plaque
11 Nov 2014 Synageva BioPharma Presents New Data From Phase 3 Study Of Sebelipase Alfa In Children And Adults With LAL Deficiency At The AASLD Meeting
10 Nov 2014 R-Tech Ueno: Completion of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in the US for the Treatment of Severe Dry Eye

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up